Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C

Hepatology Research

Volumn 40, Issue 11, 2010, Pages 1072-1081

  Kaneko, Shuichi ^a   Sata, Michio ^b   Ide, Tatsuya ^b   Yamashita, Tatsuya ^a   Hige, Shuhei ^c   Tomita, Eiichi ^d   Mochida, Satoshi ^e   Yamashita, Yukitaka ^f   Inui, Yoshiaki ^g   Kim, Soo Ryang ^h   Komada, Naoto ⁱ   Mikami, Takafumi ^j   Satoh, Shinichi ^k   Morita, Sumiharu ^l   Takaguchi, Koichi ^m   Hirashima, Noboru ⁿ   Nishio, Yuji ^o   Watanabe, Daisuke ^p   Kioka, Kiyohide ^q   Fujiwara, Kenji ^r  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Gifu Municipal Hospital   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^g Hyogo Prefectural Nishinomiya Hospital   (Japan)

^h KOBE ASAHI HOSPITAL   (Japan)

ⁱ Fujimoto Hayasuzu Hospital   (Japan)

^j Kuroishi General Hospital   (Japan)

^k Seirei Sakura Citizen Hospital   (Japan)

^l Miki Sanyo Hospital   (Japan)

^m KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^o Meitetsu Hospital   (Japan)

^p Noshiroyamamoto Medical Association Hospital   (Japan)

^q OSAKA CITY GENERAL HOSPITAL   (Japan)

^r YOKOHAMA ROSAI HOSPITAL   (Japan)

more..

Author keywords

Complete early virological response; Double filtration plasmapheresis; Elderly; Interferon therapy; Retreated patients; Treatment na ve patients

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBRINOGEN; HEPARIN; NAFAMSTAT MESILATE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANOREXIA; APPLICATION SITE BLEEDING; APPLICATION SITE INFECTION; APPLICATION SITE SWELLING; ARTICLE; BLOOD PRESSURE; CHILL; CYTOPENIA; DIZZINESS; DOUBLE FILTRATION PLASMAPHERESIS; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC DISCOMFORT; FEMALE; FEVER; HAND PARESTHESIA; HEADACHE; HEMATOMA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SEX DIFFERENCE; SHOCK; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNCONSCIOUSNESS; VASCULAR DISEASE; VIRUS LOAD; VOMITING;

EID: 77958563498     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00708.x     Document Type: Article

References (22)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Suzuki F, Akuta N, Suzuki Y et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009; 39: 1056-63.
4. Sakai A, Kaneko S, Matsushita E, Kobayashi K. Floating density of hepatitis C virus particles and response to interferon treatment. J Med Virol 1998; 55: 12-7.
5. Sakai A, Kaneko S, Kobayashi K. Immunoadsorption therapy for HCV infected chimpanzee. Nippon Rinsho 2001; 59: 1374-8.
6. Yamashita T, Arai K, Sakai A et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C. A preliminary study. Hepatol Res 2006; 36: 167-75.
7. Fujiwara K, Kaneko S, Kakumu S et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007; 37: 701-10.
8. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
9. Sezaki H, Suzuki F, Kawamura Y et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-24.
10. Kaiser S, Lutze B, Hass HG, Werner CR. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with Peginterferon alfa-2a (40KD) plus ribavirin for 72 weeks. Hepatology 2008; 48: (Suppl.):1140A.
11. Jensen DM, Marcellin P, Freilich B et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-α2b. Ann Intern Med 2009; 150: 528-40.
12. Furusyo N, Kajiwara E, Takahashi K et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-104.
13. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14: 721-9.
14. Katano Y, Kumada T, Nakano I et al. Comparison of biochemical safety between PEG-IFN α-2a and PEG-IFN α-2b. Hepatogastroenterology 2009; 56: 485-91.
15. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002; 292: 198-210.
16. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-97.
17. Sezaki H, Suzuki F, Akuta N et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-8.
18. Hirashima N, Shimada M, Iwase H, Goto H. Double filtration plasmapheresis and peginterferon plus ribavirin combination therapy for chronic hepatitis C patients non-responded by previous interferon therapy. Kanzo 2009; 50: 738-40.
19. Kim SR, Imoto S, Kudo M et al. Double- filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics. Intervilology 2010; 53: 44-8.
20. Namba T, Shiba R, Yamamoto T et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010; 14: 372-6.
21. Taniguchi M, Furukawa H, Shimamura T et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation 2006; 81: 1747-9.
22. Miyake T, Michitaka K, Tokumoto Y et al. Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation. Clin J Gastroenterol 2009; 2: 125-30.